Patient utilization survey of mirabegron prescribed for overactive bladder

Show full item record



Permalink

http://hdl.handle.net/10138/300117

Citation

Rahkola-Soisalo , P , Balcerzak , M , Ruotsalainen , J & Mikkola , T S 2019 , ' Patient utilization survey of mirabegron prescribed for overactive bladder ' , Investigative and clinical urology , vol. 60 , no. 2 , pp. 114-119 . https://doi.org/10.4111/icu.2019.60.2.114

Title: Patient utilization survey of mirabegron prescribed for overactive bladder
Author: Rahkola-Soisalo, Paivi; Balcerzak, Marcin; Ruotsalainen, Jarno; Mikkola, Tomi S.
Contributor: University of Helsinki, Department of Obstetrics and Gynecology
University of Helsinki, Department of Obstetrics and Gynecology
Date: 2019-03
Language: eng
Number of pages: 6
Belongs to series: Investigative and clinical urology
ISSN: 2466-0493
URI: http://hdl.handle.net/10138/300117
Abstract: Purpose: Mirabegron, a beta(3)-adrenoreceptor agonist, is used to treat overactive bladder. The factors affecting persistence of mirabegron use or symptom improvement are not thoroughly known, but could be related to patient characteristics. Therefore, we evaluated persistence of medication use, symptom improvement, and quality of life among Finnish mirabegron users. In addition, we assessed possible predictors of change in these variables. Materials and Methods: Participants (52 men, 118 women) with an initial mirabegron prescription were recruited nationwide from 79 pharmacies. Volunteers were interviewed at baseline and after 6 months. Subject and clinical characteristics, symptom severity, and quality of life (EQ-5D-5L) were assessed using a visual analogue scale. Results: Of 170 participants, 144 (84.7%) were reached after 6 months. The rate of persistent mirabegron use was 50.7%. Experiencing adverse effects (29.6%) was the most common reason for discontinuation of medication. A primary health care unit as a prescription site (odds ratio [OR], 2.3; 95% confidence interval [CI], 1.03-4.9) was associated with increased risk for discontinuation. Mirabegron relieved symptoms in 45.2% and enhanced quality of life in 41.7% of the participants. Age Conclusions: In this Finnish population, 50.7% of the participants continued using mirabegron after 6 months. The prescription site seemed to be important for persistent use, which may be related to patient counseling. Younger patients were more likely to benefit from treatment with mirabegron.
Subject: Medication adherence
Quality of life
Urinary bladder
Urinary incontinence
urge
URGENCY URINARY-INCONTINENCE
WOMEN
TOLERABILITY
PERSISTENCE
SYMPTOMS
ADHERENCE
EFFICACY
AGONIST
BURDEN
3126 Surgery, anesthesiology, intensive care, radiology
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Patient_utilization_survey.pdf 333.4Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record